文献速递冠心病

紫杉醇药物涂层球囊治疗ACS与非ACS患者的一年临床结局:ALLIANCE注册研究

One‐Year Clinical Outcomes of Paclitaxel‐Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-10-22

ALLIANCE是一项日本前瞻性多中心注册研究,纳入1794例新发病变患者,其中ACS占28.6%。比较紫杉醇药物涂层球囊PCI后ACS与非ACS患者的一年临床结局。结果显示ACS患者的靶病变失败率和全因死亡率均显著高于非ACS患者。

要点

  • ACS患者紫杉醇DCB术后一年靶病变失败率显著高于非ACS患者(校正HR 1.83)。
  • ACS患者一年全因死亡率亦显著升高(校正HR 2.06)。
  • 技术成功率在ACS患者中显著低于非ACS患者。

核心结论

  • 在真实世界临床中,接受紫杉醇药物涂层球囊治疗的ACS患者一年靶病变失败率和全因死亡率均显著高于非ACS患者。

研究设计与样本

  • ALLIANCE为前瞻性、多中心注册研究,纳入日本57家医疗中心1794例新发病变患者。
  • ACS患者513例(28.6%),非ACS患者1281例(71.4%),平均年龄71岁,男性占76%。
  • 采用倾向评分匹配校正ACS与非ACS患者之间的基线差异。
  • 不良事件由独立委员会裁定。

主要发现

  • ACS患者中ST段抬高型心肌梗死占34.7%,非ST段抬高型心肌梗死占33.9%,不稳定型心绞痛占31.4%。
  • 88.5%的病变使用了冠状动脉腔内影像学指导。
  • 1984处病变中仅1.1%需要DCB术后补救性支架植入。
  • ACS患者技术成功率显著低于非ACS患者。
  • 一年靶病变失败率:ACS组7.0%,非ACS组3.8%(校正HR 1.83;95% CI 1.06–3.17,p = 0.03)。

关键数值与推荐

  • 靶病变失败定义为心源性死亡、心肌梗死或临床驱动的靶病变血运重建的复合终点。
  • 技术成功定义为术后残余狭窄<40%且无限制血流的冠状动脉夹层。
  • 入组时间为2023年7月至2024年2月。

临床怎么用

  • 对于ACS患者使用紫杉醇药物涂层球囊行PCI时,需警惕一年内靶病变失败和死亡风险升高。
  • ACS患者中药物涂层球囊的技术成功率较低,提示需更谨慎地选择病变和优化操作。

局限性

  • 该研究为观察性注册研究,虽然进行了倾向评分匹配,仍可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Real-world data after percutaneous coronary intervention (PCI) using drug-coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. Aims We compared 1-year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non-ACS patients. Methods The ALLIANCE is a prospective, multicenter registry of PCI using paclitaxel DCBs. Primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, myocardial infarction (MI), or clinically driven target lesion revascularization. Secondary endpoints included all-cause mortality at 1 year. Adverse events were adjudicated by an independent committee. Propensity score matching was performed to adjust for baseline differences between the ACS and non-ACS patients. Results From July 2023 to February 2024, 1794 patients with de novo lesions (ACS 513 [28.6%] and non-ACS 1281 [71.4%]) were enrolled at 57 medical institutions in Japan. Mean age was 71 years, and 76% were male. Among ACS patients, 34.7% had ST-segment elevation MI, 33.9% non–ST-segment elevation MI, and 31.4% unstable angina. Intracoronary imaging was used in 88.5% of lesions. Bailout stenting after DCB angioplasty was required in only 1.1% of 1984 lesions. Technical success, defined as post-procedural residual stenosis < 40% and absence of flow-limiting coronary dissection, was significantly lower in patients with ACS than those with non-ACS. At 1 year, TLF occurred in 7.0% of ACS and 3.8% of non-ACS patients (adjusted HR 1.83; 95% CI 1.06–3.17, p = 0.03). All-cause mortality was 6.4% and 3.3%, respectively (adjusted HR 2.06; 95% CI 1.13–3.75, p = 0.02). Conclusions One-year TLF and all-cause mortality were significantly higher in ACS than non-ACS patients treated with paclitaxel DCBs in real-world clinical settings. Registration: Japan Registry of Clinical Trials (https://jrct.mhlw.go.jp); unique identifier: jRCT1032230218.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:One‐Year Clinical Outcomes of Paclitaxel‐Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。